These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21719339)

  • 1. [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
    Canellini G; Wasserfallen JB; Tissot JD
    Transfus Clin Biol; 2011 Aug; 18(4):493-7. PubMed ID: 21719339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogen inactivation processes applicable to cellular products: the Canadian perspective].
    Delage G
    Transfus Clin Biol; 2011 Aug; 18(4):485-7. PubMed ID: 21715210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
    Salunkhe V; van der Meer PF; de Korte D; Seghatchian J; Gutiérrez L
    Transfus Apher Sci; 2015 Feb; 52(1):19-34. PubMed ID: 25620756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen Reduction Technology in Transfusion: Where Do We Stand?
    Khurshid M; Moiz B
    J Coll Physicians Surg Pak; 2015 Nov; 25(11):779-80. PubMed ID: 26577959
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathogen inactivation in labile blood products: transfusion safety and economic impact].
    Cazenave JP
    Bull Acad Natl Med; 2006 Jan; 190(1):169-85; discussion 186-8. PubMed ID: 16878453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Costs of safety of blood and blood products].
    Seifried E; Soedel G
    Zentralbl Chir; 1995; 120(8):584-92. PubMed ID: 7571889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen reduction: state of reflection in Ireland.
    Murphy WG
    Transfus Clin Biol; 2011 Aug; 18(4):488-90. PubMed ID: 21803629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
    Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
    Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on the current opinions on blood components safety/efficacy.
    Seghatchian J
    Transfus Apher Sci; 2006 Jun; 34(3):241-2. PubMed ID: 16807111
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials for pathogen reduction in transfusion medicine: a review.
    McClaskey J; Xu M; Snyder EL; Tormey CA
    Transfus Apher Sci; 2009 Dec; 41(3):217-25. PubMed ID: 19793679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogen inactivation in platelet concentrates: the French experience].
    Cazenave JP
    Transfus Clin Biol; 2011 Aug; 18(4):478-84. PubMed ID: 21719338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transfusion of blood and products derived from blood].
    Wautier JL
    Rev Prat; 1999 Feb; 49(4):409-13. PubMed ID: 10319693
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining "adequate" pathogen reduction performance for transfused blood components.
    Goodrich RP; Custer B; Keil S; Busch M
    Transfusion; 2010 Aug; 50(8):1827-37. PubMed ID: 20374558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bacterial detection leading to pathogen inactivation].
    Morel P; Deschaseaux M; Naegelen C; Bardiaux L; des Floris MF; Pouthier F
    Transfus Clin Biol; 2005 Jun; 12(2):142-9. PubMed ID: 15894506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.